Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.

By B. Kleinschmidt-DeMasters, K. Tyler. New England Journal of Medicine, 2005

977 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Neutrophils and immunity: challenges and opportunities (2006, background): “but have been associated with devastating infections in other”
“Inside-Out” Signaling of Sphingosine-1-Phosphate: Therapeutic Targets (2008, background): “Recently, it has been reported that this combination therapy may even lead to the development of progressive multifocal leukoencephalopathy, a potentially life-threatening opportunistic infection (Kleinschmidt-DeMasters and Tyler, 2005; Langer-Gould et al., 2005).”
Identification of a Third Human Polyomavirus (2007, background): “This disorder has recently received renewed attention after the occurrence of fatal cases among patients treated with natalizumab for multiple sclerosis (22, 24).”
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS) (2011, methodology): “ADEM, acute disseminated encephalomyelitis; ADNP, activity dependent neuroprotective protein; AHR, aryl hydrocarbon receptor; APC, antigen-presenting cells; APL, altered peptide ligand; AT, adoptive transfer; C1 and CB2 receptors, cannabinoid receptors 1 and 2; CIS, clinically isolated syndrome; CNS”
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. (2009, neutral): “treatments (range) 4 (1-14) 8 (3-10) 4 (1-14)”